Content Type: Article

  • View From McDermott: House and Senate Tax Bills Would Adversely Impact Executive Pay for Tax-Exempt Organizations—Where We Are Today

    ARTICLE

    View From McDermott: House and Senate Tax Bills Would Adversely Impact Executive Pay for Tax-Exempt Organizations—Where We Are Today

    November 22, 2017

    Read time: 2 min

    Key takeaways
    Overview

    Mary Samsa and Ruth Wimer wrote this bylined article on proposed changes to executive pay practices of tax exempt organizations in the tax bills before Congress. The bills “introduce the concept of an overall compensation cap, which if exceeded, would create excise tax penalties assessed against the tax-exempt organization,” the authors wrote, which would have “a direct impact on executive pay practices and governance.”

    In depth
    Authors
    More insights

  • The IRS Has Never Won a Subpart F Sales or Services Case

    ARTICLE

    The IRS Has Never Won a Subpart F Sales or Services Case

    November 21, 2017

    Read time: 2 min

    Key takeaways
    Overview

    Lowell Yoder wrote this bylined article which discusses how the courts have rebuffed the IRS’s attempts to expand the scope of the definition of Subpart F sales income, on the basis of policy considerations, to apply to certain low-tax structures. “The IRS has never won a single litigated case” on this issue, Mr. Yoder wrote, as “courts have consistently rejected the government’s arguments to expansively apply the definition of Subpart F sales income.”

    In depth
    Authors

    Lowell D. Yoder

    Partner

    Chicago

    More insights

  • Uniform Law Commission Addresses Virtual Currency Regulation

    Uniform Law Commission Addresses Virtual Currency Regulation

    ARTICLE / CLIENT ALERT

    Uniform Law Commission Addresses Virtual Currency Regulation

    November 21, 2017

    Read time: 6 min

    Key takeaways
    Overview

    On October 9, 2017, the Uniform Law Commission released a proposed state statute, which, if adopted, will require a new type of state licensure for persons engaging in “virtual business activities.” The proposed regulation marks an effort to regulate virtual currency uniformly across all states and all token-types. As blockchain legislation is developed, the precision of definitional language is increasingly important. While virtual currency is arguably the most popular type of blockchain token today, numerous assets can and are being tokenized. As these projects and their native tokens enter the marketplace, “contextual regulation” should guide participants, rather than attempts to force everything into the same pre-existing box.

    In depth

    The blockchain community has been discussing the finer points of the Howey test and related matters to try to determine when a blockchain token (or its sale) meets the definition of “security” under the federal securities laws. Because a token can be the digitization of any asset (or of information or other items that have not traditionally been considered “assets”), we have cautioned that other regulatory schemes should be considered when evaluating how a blockchain project and its associated token should be regulated. Blockchain is a technology, not an industry, and its usage needs to be regulated in accordance with the context in which it is implemented.

    As a timely reminder of this thesis, the Uniform Law Commission (ULC) recently promulgated a proposed uniform state law for virtual currency activities, in an attempt to encourage predictability and promote assurance among virtual currency users. If adopted in any state, the law will create a new type of regulated activity requiring state licensure: entities and individuals that engage in “virtual business activities.” Virtual business activities include “exchanging, transferring, or storing virtual currency or engaging in virtual-currency administration, whether directly or through an agreement with a virtual-currency control-service vendor. . .” This definition is aimed to require licensure of providers of products and services related to Bitcoin.

    But, not exclusively Bitcoin. Under the proposal, the licensure requirement stems from engaging in “virtual business activity” with respect to “virtual currency.” For these purposes, virtual currency means a “digital representation of value that: (1) is used as a medium of exchange, unit of account, or store of value and (2) is not legal tender, whether or not denominated in legal tender.” Legal tender is defined as “a medium of exchange or unit of value, including the coin or paper money of the United States, issued by the United States or by another government.” The proposed ULC statute notes that the purpose of the definition is to encompass blockchain assets “. . .used as a substitute for ‘money’ between an obligor and obligee that have agreed to transact business as if a barter transaction is occurring, that is, where the transaction is not subject to laws that specify when the discharge of ‘debt’ occurs.”

    Whether an entity or individual will be able to continue business operations without a license, therefore, turns on this definition of “virtual currency.” This article discusses the adequacy of ULC’s definition and compares it to other definitions of the same terminology as a way to remind the community that blockchain tokens are not a homogeneous asset class capable of sustaining a bright-line definition like that of “virtual currency” proposed by the ULC.

    The Internal Revenue Service (IRS) and the Financial Crimes Enforcement Network (FinCEN) have provided guidance on virtual currency under their regulations. The IRS defines virtual currency as “a digital representation of value that functions as a medium of exchange, a unit of account, and/or a store of value. In some environments, it operates like ‘real’ currency—i.e., the coin and paper money of the United States or of any other country that is designated as legal tender, circulates, and is customarily used and accepted as a medium of exchange in the country of issuance — but it does not have legal tender status in any jurisdiction.”

    FinCEN defines the term virtual currency to be “a medium of exchange that operates like a currency in some environments, but does not have all the attributes of real currency. In particular, virtual currency does not have legal tender status in any jurisdiction.” The guidance addresses “convertible” virtual currency, defined to “either [have] an equivalent value in real currency, or [act] as a substitute for real currency.”

    In one respect, the ULC, IRS and FinCEN definitions are identical: a virtual currency is characterized by its function as a digitized “medium of exchange.” This idea seems to mean that the virtual currency does what fiat currency or legal tender does—function as a unit that people can use to pay for things.

    But the IRS and ULC definitions also include concepts of a digitized “unit of account” or “store of value.” These definitions are much less straightforward. One may reasonably argue that a token representing any collectible in the world, like artwork, baseball cards or jewelry, is a store of value. More interestingly, any tokenized personal information transferable on a blockchain ledger (e.g., health records, identity cards, internet browsing history) could represent a store of value, and indeed certain blockchain projects seek to treat them as such. Moreover, the concept of “unit of account” becomes confusing when applied to those same examples. There are plenty of other illustrations that would apparently constitute a store of value or unit of account but certainly do not immediately lend themselves to treatment as a currency. The ULC idea that any digitized asset used for barter constitutes virtual currency therefore seems overbroad. Blockchain tokens engender this kind of confusion because digitization and appearance on a ledger gives “liquidity” (that is, easy transferability) to the underlying asset, information or other item. With liquidity, apparently, comes the temptation to classify the token as some type of financial instrument.

    While financial assets are important to the world, they are not the only types of assets. More to the point, lawmakers have not intended financial regulation to apply to every commercial transaction or even to every investment transaction. Regulators and blockchain users alike should resist the temptation to apply financial services regulations to every digital asset. A digital cigar is still just a cigar.

    Authors

    David L. Taub

    Partner

    New York – One Vanderbilt Avenue

    More insights

  • FDA Creates Streamlined Review Pathway for Certain NGS-Based Tumor Profiling Tests

    FDA Creates Streamlined Review Pathway for Certain NGS-Based Tumor Profiling Tests

    ARTICLE / CLIENT ALERT

    FDA Creates Streamlined Review Pathway for Certain NGS-Based Tumor Profiling Tests

    November 21, 2017

    Read time: 6 min

    Key takeaways
    Overview

    On November 15, 2017, the FDA announced the clearance of a tumor profiling test under a novel, streamlined FDA premarket review pathway for certain next generation sequencing (NGS)-based tumor profiling tests. The creation of this pathway represents a significant, pro-industry shift with respect to the FDA regulatory requirements that might apply to tumor profiling tests. Nevertheless, substantial uncertainty remains regarding several aspects of the new pathway.

    In depth

    On November 15, 2017, the US Food and Drug Administration (FDA) announced the clearance of Memorial Sloan Kettering Cancer Center’s IMPACT tumor profiling test under a novel, streamlined FDA premarket review pathway for certain next generation sequencing (NGS)-based tumor profiling tests. Key elements of the streamlined pathway include the following:

    • Regulation as Class II medical device/eligibility for premarket notification (510(k)) pathway. The FDA’s enforcement discretion for most laboratory-developed tests (LDTs) has historically allowed—and continues to allow—clinical laboratories to offer many NGS-based tumor profiling tests without premarket review by the FDA. Insofar as a clinical laboratory voluntarily decides to submit an NGS-based tumor profiling test for FDA review, however, such test will be regulated as a Class II medical device subject to the FDA’s 510(k) requirement, and not as a Class III medical device subject to the agency’s premarket approval (PMA) requirement. The agency describes NGS-based tumor profiling tests as follows:

    A next generation sequencing (NGS) based tumor profiling test is a qualitative in vitro diagnostic test intended for NGS analysis of tissue specimens from malignant solid neoplasms to detect somatic mutations in a broad panel of targeted genes to aid in the management of previously diagnosed cancer patients by qualified health care professionals.

    • Inclusion of mutations with evidence of clinical significance and potential clinical significance in FDA-cleared indication for use, but no companion diagnostic claims. Multiplexed tumor profiling tests assess many biomarkers that may have a range of clinical evidence associated with them that is consistently changing as new science emerges. As such, the agency assigns mutations detected by NGS-based tumor profiling assays to one of three levels, depending on the evidence available to support claims for such biomarkers:
    Level Name Description Required Validation Data
    1 Companion diagnostics Provide information that is essential for the safe and effective use of a corresponding therapeutic product (e.g., a drug or biological) Analytical validation – data required for each specific biomarker

    Clinical validation – clinical study establishing either: (a) the link between the result of the test and patient outcomes or (b) clinical concordance to a previously approved companion diagnostic

    2 Cancer mutations with evidence of clinical significance Enable health care professionals to use information about tumors in accordance with clinical evidence (e.g., professional guidelines) Analytical validation – data on either on the mutation itself or via a representative approach (based on other mutations of the same type), where appropriateClinical validation – publicly available clinical evidence (e.g., professional guidelines, peer-reviewed publications)
    3 Cancer mutations with potential clinical significance Are informational or used to direct patients towards clinical trials for which they may be eligible Analytical validation – principally through a representative approach (when appropriate)Clinical validation – clinical or mechanistic rationale for inclusion in the panel (e.g., peer-reviewed publications or in vitro pre-clinical clinical models)

    Companion diagnostic (i.e., level 1) claims are explicitly excluded from the scope of the labeling for NGS-based tumor profiling tests cleared under the new pathway. Rather, tests that make companion diagnostic claims continue to be regulated Class III medical devices subject to the agency’s PMA requirement.

    • Ability to make certain modifications to the tests without requiring a new 510(k) from the FDA. Test developers will be permitted to add additional variants of the same type post-market in the panel for claims consistent with the clinical criteria established in the original submission without an additional submission. Moreover, as evidence of clinical significance becomes recognized by the clinical community, mutations can be moved from level 3 (potential clinical significance) to level 2 (clinical significance) without an additional submission, provided that the analytical validity of the test for such mutation was reviewed and established in a previous submission.
    • Recognition of the New York State Department of Health (Wadsworth Center) as a third-party reviewer. In conjunction with the IMPACT clearance announcement, FDA also announced the recent accreditation of the Wadsworth Center as a third party reviewer for in vitro diagnostics, including tumor profiling tests. Moving forward, laboratories whose NGS-based tumor profiling tests have been approved by Wadsworth do not need to submit a separate 510(k) application to the FDA. Instead, developers may choose to request that their NYS application, as well as Wadsworth’s review memorandum and recommendation, be forwarded to the FDA for possible clearance.

    Implications

    The clearance of a NGS-based tumor profiling test based primarily on the Wadsworth Center’s recommendation represents a significant, pro-industry shift with respect to the FDA regulatory requirements that might apply to such tests. Nevertheless, substantial uncertainty remains regarding several aspects of the new pathway, including the following:

    • Will clinical laboratories actually utilize the new pathway? FDA premarket review is currently required only insofar as an NGS-based profiling test is offered as a companion diagnostic. It is unclear whether the possible competitive and/or reimbursement advantages associated with offering an FDA-cleared test will be sufficient to encourage clinical laboratories to voluntarily request clearance from the agency.
    • Will reliance on the Wadsworth Center as a third-party reviewer actually speed the agency’s review? Or would laboratories be better off submitting directly to the FDA? The Wadsworth Center currently has a substantial backlog of test-specific applications for review. As such, clinical laboratories seeking FDA clearance may find it more expedient to work with the FDA itself as opposed to waiting for Wadsworth to complete its review of the file.
    • What information (if any) will FDA require beyond what Wadsworth requires? The press release announcing the clearance of the IMPACT assay stated that MSK’s submission to the FDA extended beyond the information made available to Wadsworth during its review of the test. The nature and extent of such additional information is unclear at this time.
    • Will laboratories be required to submit a new 510(k) each time they want to add a new gene to their panel? FDA explicitly calls out the addition of variants “within the existing analytically validated genes” as not triggering the requirement for a new 510(k). The agency does not, however, address the extent to which the addition of any individual gene would require a new 510(k) for the assay.
    Authors

    Paul W. Radensky , MD

    Counsel

    Washington, DC, Miami

    Michael W. Ryan

    Partner

    Washington, DC

    More insights

  • Proposed Changes for Estate, Gift and Generation-Skipping Taxes Introduced in Tax Cuts and Jobs Act

    Proposed Changes for Estate, Gift and Generation-Skipping Taxes Introduced in Tax Cuts and Jobs Act

    ARTICLE / CLIENT ALERT

    Proposed Changes for Estate, Gift and Generation-Skipping Taxes Introduced in Tax Cuts and Jobs Act

    November 20, 2017

    Read time: 3 min

    Key takeaways
    Overview
    In depth

    UPDATED as of November 16, 2017: On November 16, the US House of Representatives passed its version of the Tax Cuts & Jobs Act. On that same day, the Senate Finance Committee approved its tax plan, although the statutory language of the bill was not released.

    The House-passed legislation included the estate, gift and generation-skipping tax changes described below—doubling of the exemption base, repeal of the estate and generation-skipping taxes beginning in 2025 and a drop in the gift tax rate from 40 percent to 35 percent starting in 2025.

    The Senate plan does not call for the repeal of these taxes at any time. It mirrors the increase in exemptions under the House bill, but starting in 2026, the exemptions would revert back to the pre-2018 levels, although they would continue to be indexed for inflation.

    Under both the House and Senate versions, indexing is based on a different measure called the “chained CPI.” The Congressional Budget Office expects that inflation measured by the chained CPI will be about 0.25 percentage points lower compared to the results using the traditional CPI adjustment. Our unofficial calculation of how this impacts the estate, gift and generation skipping exemptions for 2018—if the legislation as proposed is enacted—is that those exemptions would be $11.18 million, just slightly less than the $11.2 million figure that would apply using the traditional CPI measure.

    ***

    The Tax Cuts and Jobs Act introduced by House Ways and Means Committee Chairman, Kevin Brady, on November 2, 2017, if enacted in its current form, would make the following changes to the federal estate, gift and generation-skipping tax regimes:

    1. After December 31, 2017, the estate, gift and GST exemptions each increase to $10 million, plus the inflation adjustment applicable under current law. As the previously announced inflation adjustment figure for 2018 is $5.6 million, the new exemption figures starting January 1 would be $11.2 million.
    2. Other than the exemption figures, the estate, gift and GST tax regimes would remain unchanged until 2024.
    3. Effective January 1, 2024:
    • The estate and GST taxes would be repealed;
    • The step-up in basis for assets held at death would be retained; and
    • The gift tax rate would drop from 40 percent to 35 percent.

    Please stay tuned for further developments as these provisions may change or be eliminated as the tax legislation moves through Congress.

    Authors

    Richard A. Lang

    Partner

    Chicago

    More insights

  • Tax Court Says IRS’s ‘Drift-Net’ Argument to Expand Privilege Waiver Must Be Anchored in Principles

    Tax Court Says IRS’s ‘Drift-Net’ Argument to Expand Privilege Waiver Must Be Anchored in Principles

    ARTICLE

    Tax Court Says IRS’s ‘Drift-Net’ Argument to Expand Privilege Waiver Must Be Anchored in Principles

    November 17, 2017

    Read time: 2 min

    Key takeaways
    Overview

    Robin Greenhouse, Roger Jones, Andrew Roberson and Kevin Spencer wrote this bylined article on Estate of Levine v. Commissioner, in which the US Tax Court rejected an IRS attack on privilege waiver principles. The authors wrote that given “a recent pattern of the IRS aggressively arguing against the assertion of privilege and work-product protections in tax audits,” taxpayers should “resist the IRS’s attempts to expand the waiver concept beyond reason and principle.”

    In depth
    Authors

    Roger J. Jones

    Counsel

    Chicago

    More insights

  • New Tools to Help Run M&A Deals More Effectively

    ARTICLE

    New Tools to Help Run M&A Deals More Effectively

    Fall 2017

    Read time: 2 min

    Key takeaways
    Overview

    Byron Kalogerou co-authored this bylined article on the latest online tools provided by the ABA Task Force on Legal Project Management in M&A (which he co-chairs) to help transactional practitioners run M&A deals more efficiently and effectively. They join other tools that have already been posted electronically.

    In depth
    Authors

    Byron S. Kalogerou

    Partner

    Boston

    More insights

  • Bad Old Days a Cautionary Tale for Justice Reform

    ARTICLE

    Bad Old Days a Cautionary Tale for Justice Reform

    November 14, 2017

    Read time: 2 min

    Key takeaways
    Overview

    Robert Cordy, as a former Massachusetts Supreme Judicial Court Justice and gubernatorial legal counsel, wrote this bylined article on a current re-examination of the state’s criminal justice policies, cautioning that there should be review of “not just of the cost of the current laws (which admittedly have been substantial in human terms) but also the benefits — or rather the cost to the public of an environment less secure from crime in their streets and their neighborhoods.”

    In depth
    Authors
    More insights

  • Post-Escobar Guardrails and Policy-Setting Relators

    Post-Escobar Guardrails and Policy-Setting Relators

    ARTICLE

    Post-Escobar Guardrails and Policy-Setting Relators

    November 14, 2017

    Read time: 2 min

    Key takeaways
    Overview

    Rebecca Martin wrote this bylined article on the Fifth Circuit’s ruling in U.S. ex rel. Harman v. Trinity Industries, a False Claims Act case where the court “handed a resounding defeat to the relator” by overturning a jury verdict. The Court “gave a hard pushback to relators who pursue cases in the name, but against the wishes, of the government,” Ms. Martin wrote, adding that this “coincides nicely” with a US Justice Department effort to dismiss declined False Claims Act cases.

    In depth
    Authors
    More insights

  • ANDA Update

    ANDA Update

    ARTICLE / OTHER

    ANDA Update

    November 2017

    Read time: 3 min

    Key takeaways
    Overview

    In denying a brand manufacturer’s motion to dismiss antitrust counterclaims and motion to stay pending appeal of a preliminary injunction order, the US District Court for the District of New Jersey placed significant weight on practical factors, such as maximizing judicial economy and streamlining substantive issues. Fresenius Kabi USA, LLC v. Fera Pharm., LLC, Case No. 15-3654 (D.N.J., May 19, 2017) (McNulty, J).

    In depth
    Authors
    More insights